title: The Current Status of Immunotherapies in Esophagogastric Cancer.
abstract: This review summarizes completed and ongoing studies evaluating the activity of immune checkpoint inhibitors in esophagogastric cancer.
authors.affiliation: Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, Room 1035, New York, NY 10065, USA. Electronic address: kug@mskcc.org.
authors.forename: Geoffrey Y
authors.initials: GY
authors.lastname: Ku
mesh_terms: D004938:Esophageal Neoplasms / Q000628:therapy*; D004943:Esophagogastric Junction; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D061026:Programmed Cell Death 1 Receptor; D013274:Stomach Neoplasms / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D061026:Programmed Cell Death 1 Receptor
keywords: Adenocarcinoma; Esophageal; Gastric; Immune checkpoint; Immunotherapy; PD-1; PD-L1; Squamous cell carcinoma